US-based medical technology company Lensar has received the US Food and Drug Administration (FDA) 510(k) clearance for its Ally adaptive cataract treatment system.

The next-generation Ally is said to be the first FDA-cleared platform for femtosecond-laser-assisted cataract surgery procedures in a single, sterile environment.

Lensar is planning for a limited launch of Ally systems to surgeons in the third quarter of this year. After the launch, the company will make Ally widely available to cataract surgeons next year.

Ally’s reduced footprint and superior ergonomics offer surgeons to improve their efficiencies in any operating room or in-office surgical suite.

The system provides adaptive intelligence to autonomously identify cataract density, optimise fragmentation patterns, and energy settings.

The cataract surgery platform aims to reduce the overall energy provided to complete the cataract procedure efficiently and contribute to a faster visual recovery and improved patient outcomes.

The company said that the latest offering when combined with astigmatism correction technology, has the potential to set new benchmarks for femtosecond laser cataract surgery.

Lensar chief executive officer Nick Curtis said: “We are elated to bring this proprietary technology to cataract surgeons.

“Our mission has been to develop a platform where surgeons can seamlessly perform the entire FLACS procedure in a single setting, improve workflow efficiencies, and most importantly, help surgeons deliver better outcomes through the advanced technologies in the ally system.

Curtis added: “We are seeing an overwhelmingly positive response to the Ally system. Over 125 surgeons have experienced Ally firsthand, during demonstrations performed at the American Society of Cataract and Refractive Surgery Annual Meeting in April, and more recently at our home office.”

Ally system also includes Lensar’s proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.